key: cord-0839551-aaib24oc
authors: Taga, Arens; Lauria, Giuseppe
title: COVID‐19 and the peripheral nervous system. A 2‐year review from the pandemic to the vaccine era
date: 2022-03-14
journal: J Peripher Nerv Syst
DOI: 10.1111/jns.12482
sha: 1082dd8b758fbfa5ec6113ec5653912eb12ae8a2
doc_id: 839551
cord_uid: aaib24oc

Increasing literature has linked COVID‐19 to peripheral nervous system (PNS) diseases. In addition, as we move from the pandemic to the vaccination era, literature interest is shifting towards the potential association between COVID‐19 vaccines and PNS manifestations. We reviewed published literature on COVID‐19, COVID‐19 vaccines and PNS manifestations between 1 January 2020 and 1 December 2021. For Guillain‐Barré syndrome (GBS), isolated cranial neuropathy (ICN) and myositis associated with COVID‐19, the demographic, clinical, laboratory, electrophysiological and imaging features were included in a narrative synthesis. We identified 169 studies on COVID‐19‐associated complications, including 63 papers (92 patients) on GBS, 29 papers (37 patients) on ICN and 11 papers (18 patients) on myositis. Additional clinical phenotypes included chronic inflammatory demyelinating polyneuropathy, vasculitic neuropathies, neuralgic amyotrophy, critical care‐related complications, and myasthenia gravis. PNS complications secondary to COVID‐19 vaccines have been reported during randomized clinical trials, in real‐world case reports, and during large‐scale surveillance programs. These mainly include cases of GBS, Bell's palsy, and cases of neuralgic amyotrophy. Based on our extensive review of the literature, any conclusion about a pathophysiological correlation between COVID‐19 and PNS disorders remains premature, and solely supported by their temporal association, while epidemiological and pathological data are insufficient. The occurrence of PNS complications after COVID‐19 vaccines seems limited to a possible higher risk of facial nerve palsy and GBS, to a degree that widespread access to the ongoing vaccination campaign should not be discouraged, while awaiting for more definitive data from large‐scale surveillance studies.

An increasing body of literature, including cohort studies, [1] [2] [3] [4] [5] [6] [7] [8] [9] has linked COVID-19 to the development peripheral nervous system (PNS) diseases. However, findings are divergent due to methodological differences and largely variable sample sizes. Few studies used a prospective design 8, 10 and focused on defined diagnoses rather than symptoms alone. 5 Some studies relied on self-administered questionnaires and others on hospital records, and in some cases, the diagnosis was not confirmed by neurologists. 8 Individual diagnoses were not always supported by laboratory, electrodiagnostic (EDX), and pathology findings. As a result, PNS involvement was quite variable, ranging from 1.3% to 9.5% of cases 4, 8 if individual diagnoses were considered (eg. neuropathy, myopathy, etc.), and up to 70.2% if individual symptoms were included (eg. myalgia, paresthesia, etc.). 3 In a very large retrospective cohort including 1760 COVID-19 patients from a single epidemic hotspot (Bergamo, Italy), 6 Here, we present a comprehensive narrative on 169 studies published between 1 January 2020 and 1 December 2021 on PNS involvement. Our main aims were investigating the association between COVID-19 and PNS diseases and understanding whether COVID-19 had any clinically meaningful impact on clinical presentation, diagnosis, and therapeutic approaches. Furthermore, as we are moving from the pandemic to the vaccination era, we provide an overview of the potential association between COVID-19 vaccines and PNS diseases discussing the findings reported so far.

Given the extent and heterogeneity of the topics reviewed in this paper, we aimed to provide a synthetic albeit comprehensive narrative on the published literature. However, our approach was not meant to be systematic, as commonly defined by Cochrane and PRISMA statements. A systematic approach has been attempted in the past, during the early and later stages of the pandemic, but on GBS cases only. 11, 12 The data we extracted therefore were not incorporated in a metaanalysis, but were instead the basis for our expert opinion commentaries.

We searched MEDLINE through PubMed, Web of Science and Cochrane library databases, and Google Scholar database. The search strategy included the terms ("Coronavirus" OR "Coronavirus disease"

OR "novel coronavirus" OR "Severe acute respiratory syndrome coronavirus 2" OR "COVID-19" OR "nCoV 2019" OR "SARS-CoV-2" OR "Long COVID" OR "COVID vaccine" OR "BNT-162b2" OR "Pfizer" OR "mRNA-1273" OR "Moderna" OR "Ad26.COV2.S" or "Johnson&Johnson" OR "ChAdOx1" OR "AstraZeneca" OR "Vaxzevria") AND ("peripheral nervous systems" or "PNS" or "Guillain-Barré syndrome" OR "GBS" OR "Miller Fisher syndrome" OR "MFS" OR "acute inflammatory demyelinating polyneuropathy" OR "AIDP" OR "acute motor axonal neuropathy" OR "AMAN" OR "acute motor sensory axonal neuropathy" OR "AMSAN", OR "chronic inflammatory demyelinating polyneuropathy", OR "CIDP", OR "nerve" OR "neuropathy" OR "cranial neuropathy" OR "Bell's palsy" OR "neuritis" OR "vasculitis" OR "polyneuropathy" OR "multineuritis" OR "neuralgic amyotrophy "OR "Parsonage Turner Syndrome" OR "plexus" OR "small fiber neuropathy" OR "dysautonomia" OR "postural orthostatic tachycardia syndrome" OR "POTS" OR "muscle" OR "myopathy" OR "myositis" OR "dermatomyositis" OR "myasthenia gravis" OR "MG" OR "neuromuscular junction" OR "critical illness myopathy" OR "critical illness polyneuropathy".

We restricted our search to peer-reviewed studies, published in English, and importantly, to papers published between 1 January 2020 and 1 December 2021.

The causal association between COVID-19 and nervous system manifestations has been solely inferred from their temporal co-occurrence. Two patterns have been described: (a) neurological complications occurring together with COVID-19 symptoms and suggesting a direct viral mechanism ("para-infectious" hypothesis), such as neuroinvasion;

(b) neurological complications developing after the initial infectious symptoms and supporting indirect mechanisms ("post-infectious" hypothesis), likely immune-mediated.

The ability of SARS-CoV-2 to invade the nervous systems has been conjectured based on the known neuroinvasive capabilities, both in vivo and in vitro, of SARS-CoV and MERS-CoV, with whom the etiological agent of COVID-19 (ie, SARS-Cov-2) has 79.5% and 50% gene homology, respectively. 13 Given the early occurrence of anosmia and ageusia, one hypothesis is that olfactory, trigeminal, or gustative terminals could be entry routes for the virus, which could then spread to the central nervous system (CNS) through retrograde axonal transport and trans-synaptic transfer. 14 Lower cranial nerves could be additional entry points, causing early lower brain stem involvement and possibly explaining some peculiar features of COVID-19, such as hypoxia out-of-proportion to dyspnea and the frequent occurrence of syncope. 15 Alternative mechanisms of neuroinvasion that could apply both to the CNS and PNS include entry through circulating immune cells, infection of the vascular endothelium or crossing of the bloodbrain barrier or of the blood-nerve barrier. 14 A wealth of studies, including case reports and case series 16 (Tables 1 and 2 References [57,67, [76] [77] [78] [79] 98] [67, [80] [81] [82] 97] [ [83] [84] [85] [ 65, 71, 82, [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [ No. of patients % (n/total) 59 Age of onset (mean ± SD, range)

58.1 ± 13.8 58.6 ± 17.2 33.4 ± 20.7 45 ± 28.2 50.9 ± 20.4 55.2 ± 17.3 Gender %males (n/total) 60 62 .0% (57/92) Onset relative to COVID mean ± SD days (range) 13 .5 ± 8.7 (À8, 33) 9.6 ± 8.9 (À3, 27) 13.6 ± 12.8 (3, 18) 15.7 ± 5.5 (10, 21) 11.4 ± 6.3 (3, 21) 12.2 ± 8.3 (À8, 33) GBS phenotype % (n) 24 In situ hybridization localized the RNA to inside the sarcolemma. 24 These data suggest that although possible, the direct invasion mechanism is not a universal phenomenon, and its clinical significance remains unclear.

The "post-infectious" immune-mediated hypothesis is supported by evidence that COVID-19 causes a proinflammatory state due to the release of multiple cytokines, such as IL1, IL6, and TNF, as well as immune-cell hyperactivation. 14 The umbrella term "cytokine storm"

has been used to describe this phenomenon, although its appropriateness for COVID-19 is still debated. 25 In the lung, this has been linked to the progression towards acute respiratory distress syndrome (ARDS). 25 This mechanism has been proposed for other systemic complications of the disease, such as skin vasculitis, Kawasaki-like syndrome, myocarditis, and hemophagocytic lymphohistiocytosis. 25 Similar to other systems, vasculitis may affect cerebral small vessel causing stroke. 26 In the PNS, individual reports of multiplex mononeuropathy suggested possible vasculitis that, however, could not be confirmed due to the lack of neuropathological data. [27] [28] [29] [30] The isolation of pathogenic anti-neuronal antibodies (eg, anti-contactin-associated protein 2), 31 has been invoked as a proof of the immune-mediated mechanism underlying post-COVID-19 myelitis and encephalitis. 14 Although uncommon in our review (Table 1) , the presence of disease-specific antibodies, such as anti-ganglioside antibodies has been observed in post-COVID neuropathies. The shared pathogenetic hypothesis is that the molecular mimicry between SARS-CoV-2 surface proteins and self-antigens may lead to the production of autoantibodies targeting neuronal antigens or nodal/ paranodal proteins in the CNS and PNS, respectively. Although there is clinical evidence that some of the high-affinity SARS-CoV-2-neutralizing antibodies cross-react with human self-antigens, including self-antigens found in the CNS, their ability to cross the brain-or nerve-blood barrier has not been demonstrated. 32 By using in silico analysis, Keddie et al demonstrated that there is no linear homology between SARS-CoV-2 proteins and any axonal or myelin surface proteins, thus, making the molecular mimicry hypothesis unlikely. 33 An alternative immune-mediated hypothesis has been proposed by Suh et al. 23 The authors conducted a post-mortem histopathological study on the psoas muscle and femoral nerve of 35 patients who died of severe COVID-19 compared to 10 critically-ill patients who were negative for SARS-CoV-2 but died during the COVID-19 pandemic. 23 They observed overexpression of the major histocompatibil- An additional effect of uncontrolled systemic inflammation is the occurrence of coagulopathy resulting mainly, although not exclusively, in venous thromboembolic events. 35 In the CNS, this has been linked to an increased incidence of stroke in specific epidemiological scenarios, while its significance for PNS complications remains unclear.

Some of the neuropathies secondary to COVID-19 in our review could be secondary to thrombotic mechanisms, but much needed pathological data remain unavailable.

We identified 63 publications and 92 patients, 36 100 and UK (25 cases, including 13 "definite" and 12 "probable COVID-19"). 33 We did not include these additional 66 cases in Table 1 104 In the UK and Italian COVID-19

cohorts, a higher than expected frequency of AIDP was noted, 33, 99 although it was statistically significant only in one study. 99 This likely reflected a higher than expected prevalence of axonal forms in their GBS control cases (up to 41.2%; seven out of 17 cases). 99 In a separate study on the same Italian COVID-19 cohort, the electrophysiological features of AIDP were compared to non-COVID-19 AIDP. 107 Distinctive features among COVID-19 patients were higher percentage of cases with absent F waves, which was attributed to motor neuron hypoexcitability, and increased duration of distal compound motor action potential (CMAP) without changes in distal latencies, which was interpreted as conduction slowing within muscle fibers. A major confounder in this study was that a large proportion of COVID-19 AIDP patients had a critical illness, which in some of the cases was due to the underlying lung infection. 107 Laboratory testing disclosed albumin-cytological dissociation in 75.3% of cases, comparable to the 64% seen in the overall GBS population, 104 Unexpectedly, among the 11 MFS cases only one tested positive for anti-GD1b 93 and none for anti-GQ1b, as compared to 90% positivity in non-COVID-19 MFS patients. 104 The same finding was reported in the UK cohort. 33 Brain and spine MRI were performed in 28 and 31 cases. Common findings, although present in less than 30% of cases, included enhancement of cranial nerves, spinal nerve roots, and cauda equina.

Far from being specific to COVID-19, these findings added diagnostic certainty to GBS diagnosis.

The initial concern that intravenous immunoglobulin (IVIG) might impair the humoral immunity towards SARS-CoV-2 prompted some clinicians to prefer plasmapheresis (PEX) as first-line therapy. However, there was no report of clinical deterioration after IVIG, which was the preferred treatment in 81.3% of cases (74 patients). This was the same approach reported in the GBS/COVID-19 cohorts. 33, 99, 100 The data on clinical outcomes were scarce among published cases. 33, 99 However, these percentages are higher than the 20% reported in the literature for the general GBS population. 104, 108 The mortality rate among COVID-19/ GBS cases was 6.5% (Table 1) , similar to reports in the general population. 105 No deaths related to GBS and neuromuscular weakness were reported in the three cohort studies. 33, 99, 100 Overall, based on our extensive review of published literature, GBS phenotype among COVID-19 patients did not show distinctive features. This conclusion was also reached by the UK cohort study. 33 Few clinical findings, such as frequent need for ICU stay 99,100 and invasive ventilation, 33 and possibly more severe disability outcomes ( Larger and longer case-control studies and surveillance data from multiple geographic regions will ultimately be able to prove any epidemiological association between COVID-19 and GBS. In this regard, a recent international prospective cohort study by the International GBS Outcome Study consortium enrolled incident GBS cases between 30 January 2020 and 30 May 2020 and found no increase in patient recruitment during the pandemic. 110 A higher prevalence of COVID-19 was noted among GBS cases when compared to the general population, but this could have been secondary to substantial recruitment bias. 110 

Isolated or multiple cranial neuropathies not associated with polyneuropathy or other neurological disorders have been reported (Table 2) . 93 cytic infiltrate and axonal damage on brain autopsy. 112 Evidence that these symptoms may be transitory in the majority of patients has suggested a competitive mechanism on the olfactory receptors rather than a permanent cell damage. 137 For yet unknown reasons, olfactory symptoms are strongly associated with gustatory dysfunction (ie, ageusia or dysgeusia). 136 We identified two literature reports of isolated optic neuropathy. 113 The facial nerve has attracted much interest given the frequent occurrence of gustatory symptoms among COVID-19 patients.

Reports of severe unilateral dysgeusia leading to the diagnosis of ipsilateral facial palsy however remain isolated. 68 Three case of hypoglossal nerve neuropathy have been reported. [132] [133] [134] All occurred unilaterally and were temporally related with either endotracheal intubation or prone positioning, suggesting a iatrogenic etiology.

Based on available evidence, any direct etiological association between COVID-19 and cranial neuropathies seems inconclusive.

Larger and longer case-control studies will be needed to address any causal link.

Because GBS patients reported in Table 1 were not prospectively followed up, it is unclear whether some of them were in fact acuteonset chronic inflammatory demyelinating polyneuropathy (CIDP), which is reported in up to 5% to 16% of patients in pre-COVID-19

studies. 147 In our literature review, we did not find any report linking COVID-19 to a new diagnosis of CIDP.

The potential of COVID-19 to precipitate CIDP has been pro- with a systemic immune-mediated process similar to multisystem inflammatory syndrome. 28 The potential of COVID-19 to cause small fiber neuropathy (SFN) has been postulated based on the occurrence of autonomic dysfunction among COVID-19 patients presenting with GBS (Table 1 ). In one of such cases, autonomic dysfunction in the form of profuse sweating, constipation and erectile dysfunction preceded motor symptoms. 97 In the ALBACOVID registry, 2.5% of patients were diagnosed with autonomic dysfunction. 2 Although growing literature interest is directed toward SFN in "long COVID" (see below), in our review we did not find any additional literature report on isolated SFN being diagnosed in the acute setting.

Myalgia and asymptomatic CK elevation are common findings among Growing literature has reported the occurrence of myositis in the setting of COVID-19 (Table 4 ). 10,157-164 These include patients with classic proximal myopathy, 10,157-159,164 cases with marked bulbar involvement, 160 presentations consistent with dermatomyositis, 161 including cases with amyopathic dermatomyositis and interstitial lung disease. 165, 166 In the majority of cases, the diagnosis of myositis was determined based on clinical presentation supported by laboratory findings (ie, CK elevation, and, when available, myositis-specific autoantibodies) in the setting of a molecular diagnosis of viral (ie, SARS-CoV-2) infection. In few patients, the diagnosis was confirmed by muscle biopsy 10,160 and/or muscle MRI. 158, 160, 162 In one case, electron microscopy ruled out direct viral invasions as pathophysiological mechanism of muscle damage. 160 A dramatic case of limb ischemia complicated by severe muscle injury, inflammation and compartment syndrome was attributed to COVID-19-induced hypercoagulability. 163 In a case series of COVID-19-associated paraspinal myositis, 162 seven out of nine patients who underwent spine MRI for back pain, lower extremity weakness, or lower extremity paresthesia were found to have edema and enhancement of the paraspinal muscles (ie, erector spinae and multifidus paraspinal muscles) at the lumbar level.

Although the clinical relevance of these finding was unclear, the authors hypothesized that myositis could be relatively common in COVID-19 patients. It cannot be ruled out that the paraspinal involvement could have been secondary to a protracted immobilization among severe COVID-19 patients. 184 and on similar experiences with influenza A and B infection, early administration of IVIG has been proposed as a potential preventative intervention for CIM/CI, although evidence is still limited to individual case reports. 185 Prone positioning has been found beneficial in ARDS and successfully translated to the COVID-19 care in the ICU, but it has also posed unexplored challenges. 186 In the setting of PNS disease, entrapment neuropathies have been the most common complication. [187] [188] [189] [190] [191] Among 83 patients admitted for COVID-19-related ARDS and requiring prone ventilation, 12 (14.5%) developed this complication. 187 The most frequent sites of injury were ulnar nerve (28.6%), radial nerve (14.3%), sciatic nerve (14.3%), brachial plexus (9.5%), and median nerve (9.5%). A similar study in Italy involved 135 COVID-19 patients requiring prone ventilation of whom 7 (5.2%) developed entrapment neuropathies, with again the ulnar nerve (five out of seven) and the brachial plexus (two out of seven) being the most frequently affected.

In the majority of cases, axonotmesis was evident on neurophysiological exams. 188 These percentages are higher than expected based on the clinical trials that have validated the use of prone ventilation in the pre-COVID era. 186 One hypothesis is that patients with COVID-19 ARDS may be more vulnerable to peripheral nerve injury, but no control patients were included to address this question in both studies. 187, 188 Long and repeated prone positioning, and the comorbidities associated with severe COVID-19 (eg, diabetes, obesity, old age) rather than direct mechanisms could explain a predisposition to more frequent nerve injury among COVID-19 patients.

Compression of the lateral femoral cutaneous nerve at the level of the anterior-superior iliac spine or inguinal ligament may be a relatively uncommon but specific complication of prone positioning. 192, 193 Additional complications have been linked to nerve injury during endotracheal tube insertion or as a result of its displacement during prone positioning. A case of Tapia syndrome (ie, concomitant paralysis of hypoglossal and vagus nerves) has been described in one COVID-19 patient. 132 At least one of the two cases of hypoglossal paralysis reported in Table 2 was likely due to orotracheal intubation and prone ventilation rather than to multineuritis as hypothesized. 133 has been reported in up to 38% and 18% of patients, respectively. 196, 197 These findings are supported by impaired performance on neuropsychological testing and by evidence of frontal and parietal hypometabolism on FDG-PET. 198, 199 Proposed mechanisms include long lasting neuronal damage caused by hypoxia, neuroinflammation, or virus permanence. 200 More recently, an increasing body of literature has suggested an involvement of the PNS during the later stages of COVID-19. As pointed above, anosmia and dysgeusia besides being common early COVID-19 symptoms, seem to persist in up to 27% of patients after the acute phase, possibly suggesting irreversible damage to the nerve terminals or the sensory receptor cells. 197 Pain is one of the most common long-term PNS symptoms after COVID-19, reported by up to 30% of patients depending on the cohorts. 200 Localized pain, such as chest pain, joint pain, and headache is the most frequent complaint, but there is an increasing number of reports on a more diffuse and ill-defined pain among long-haulers, frequently associated with descriptors such as fatigue, myalgia, and paresthesia. 196, 197, 200 One hypothesis is that the release of proinflammatory cytokines during the acute infection may cause hypersensitization of peripheral nociceptors followed by plastic changes and central sensitization during the chronic stage.

Muscle atrophy seems to be an early feature of severe COVID-19, in possible relation to the release of proinflammatory cytokines (TNF-alpha, IL-1 and IL-6), a mechanism that has been well established in other diseases, such as AIDS and cancer, where muscle loss is a prominent symptom. 201 Additional mechanisms, specific to COVID-19, could be prolonged immobilization with type 2 muscle atrophy, use of high-dose steroids and neuromuscular blockade, and nutritional deficiencies related to prolonged feeding assistance. Whether these manifestations are reversible and their long-term impact on COVID-19 patients remains to be determined, and prospective studies are still lacking.

Fatigue has been described in as high as 53% of patients at The spectrum of symptoms associated with long COVID has prompted comparisons with myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS). 208 This is not surprising as ME/CFS could be secondary to viral infections such as EBV, rotavirus, or HHV-6, among others. 209 One may hypothesize that at least some of the symptoms observed with long COVID could be a non-specific response to an infectious (viral) illness in predisposed individuals, as it has been proposed for ME/CFS. 208 Despite the mounting pressure from the public opinion, which parallels the increasing frequency of referrals to neurology for "long-COVID" symptoms, the quality and quantity of literature on this topic is still limited. Many questions remain unanswered, including the temporal criteria for defining "long-COVID" itself, whether this is a single entity or an umbrella category for multiple and unrelated presentations, and, more importantly, whether it is secondary to a non-neurological pathological process, such as a psychiatric disorder (such as post-traumatic stress disorder or depression), or expression of the pulmonary and/or cardiac involvement in the early stages of the disease. The potential of COVID-19 vaccines to cause GBS, particularly the adenovirus vector-based, vaccines has been initially suggested by cases that occurred during the phase III clinical trials. The association between GBS and vaccination has been long debated since initial reports of increased incidence of GBS after the swine influenza vaccine during the USA/New Jersey 1976 vaccination campaign. 104 Thereafter, similar concerns have been raised for multiple vaccines, including oral polio, DPT, rabies, hepatitis B, and quadrivalent conjugated meningococcal vaccines. 220 However, large case-control studies have failed to show causal association. 220 where it was available), whereas in a single case it was AMSAN.

Patients were treated with conventional therapies (ie, IVIG) and the outcome was positive, with GBS disability score ≤ 2 in 10 out of 14 cases where this information was available. The occurrence of GBS after mRNA-based vaccines has been also reported, although less commonly (n = 5 cases). 223, 227, 228, 233, 234 237 Patients presenting with GBS after AstraZeneca vaccine had more frequent facial and bulbar involvement than the historical cases, and more commonly they had the bifacial weakness and distal paresthesia GBS variant, similar to the above-mentioned reports. [237] [238] [239] Large surveillance programs to identify any excess of GBS cases In contrast, during surveillance studies for the mRNA-based vaccines, no vaccine-outcome association, including the occurrence of GBS, met the pre-specified requirement for a signal. 244 This may suggest that, similar to thrombotic complications (see below), antigens mimicking neural components may be related to the structure of the adenovirus vectors, and this would explain the relative safety of mRNA vaccines. 245 Overall, these data are preliminary and should be taken cautiously, without leaping to costly conclusions. 246 

In our review, we found isolated reports of "acute onset" CIDP following Moderna 259 and AstraZeneca vaccines, 235, 260 in all cases 3 weeks after the first dose. Of note, one of the cases had a similar presentation years prior after the influenza vaccine, but he was asymptomatic since then. 259 All cases had a good recovery after standard treatment. In the UK cohort on GBS within 4 weeks after COVID-19 vaccines, four out of 16 patients were diagnosed with acute-onset CIDP. 237 No clinical or neurophysiological exams are available for these patients, besides the fact that two were subsequently re-treated with IVIG, one patient with corticosteroids, and one with plasma exchanges with good outcome. 237 In the pre-COVID era, the Italian CIDP database identified vaccination as the anteceding event in 1.5% of 411 patients 1 to 42 days before the diagnosis of CIDP. 261 Given the chronic nature of CIDP and the fact that its diagnosis requires a progression over 8 weeks, attributing its onset to a single event (ie, vaccination) is challenging.

As an example, one of the post-COVID-19 vaccine CIDP patients had also received the influenza vaccine 6 weeks prior to the onset of symptoms, while the COVID-19 vaccine had been administered 3 weeks prior. 235 When reviewing the potential of COVID-19 vaccines to exacerbate or worsen CIDP in patients with an established diagnosis, we did not find any report so far. Our current knowledge on the use of vaccines of any kind in patients with a prior CIDP diag- 272 Interestingly, one patient complained of onset of pain around the injection site that spread to the shoulder and the arm. 270 Overall, the incidence of post-vaccination Parsonage- strength, consistency, specificity, temporality, biologic gradient, plausibility, coherence, experiment, and analogy. 282 So far temporality and, possibly, plausibility seem to be the only criteria met by the conditions reviewed in this paper. Therefore, based on available data, any conclusion about a pathophysiological correlation between COVID-19, vaccines and PNS disorders remains premature, while epidemiological, clinical and pathological data are insufficient. 283 The occurrence of PNS complication after COVID-19 vaccines seems very rare and limited to a possible higher risk of facial nerve palsy and possibly GBS, however, in a range that should not raise any concern on the need to pursue the vaccination campaign. Based on experiences with other vaccination campaigns and data coming from adverse monitoring systems, there is widespread consensus that the benefits of vaccination outweigh the risks related to adverse events.

Although large cohort studies are still lacking, there is early evidence that the administration of COVID-19 vaccines, specifically the Pfizer vaccine, among patients with known history of GBS is not associated with a significant risk of relapse. 284 

Clinical features of 1487 COVID-19 patients with outpatient management in the Greater Paris: the COVID-call study

Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry

Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019

Surveillance Study of Acute Neurological Manifestations among 439 Egyptian Patients with COVID-19 in Assiut and Aswan University Hospitals

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Neurologic manifestations in 1760 COVID-19 patients admitted to Papa Giovanni XXIII Hospital

Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study

A prospective study of neurologic disorders in hospitalized patients with COVID-19 in New York City

New onset neurologic events in people with COVID-19 in 3 regions in China

Covid-19-Associated myopathy caused by type I interferonopathy

Guillain-Barre syndrome associated with SARS-CoV-2 infection: a systematic review and individual participant data meta-analysis

Guillain-Barre syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases

The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients

Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review

Syncope at SARS-CoV-2 onset

Cerebrospinal fluid findings in COVID-19 patients with neurological symptoms

Cerebrospinal fluid in COVID-19: A systematic review of the literature

Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients

Neuropathology of COVID-19 (neuro-COVID): clinicopathological update. Free Neuropathol

Neuropathology of patients with COVID-19 in Germany: a post-mortem case series

Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)

Ultrastructural evidence of direct viral damage to the olfactory complex in patients testing positive for SARS-CoV-2

Skeletal muscle and peripheral nerve histopathology in COVID-19

Diaphragm pathology in critically ill patients with COVID-19 and postmortem findings from 3 medical centers

Cytokine storm

Large and small cerebral vessel involvement in severe COVID-19: detailed clinical workup of a Case Series

Neuralgic amyotrophy associated with COVID-19 infection: a case report and review of the literature

Parsonage-turner syndrome associated with SARS-CoV2 (COVID-19) infection

Pure sensory neuralgic amyotrophy in COVID-19 infection

Neuralgic amyotrophy following infection with SARS-CoV-2

Immune-mediated neurological syndromes in SARS-CoV-2-infected patients

Do cross-reactive antibodies cause neuropathology in COVID-19?

Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barre syndrome

Type I interferon signature in Chilblain-like lesions associated with the COVID-19 pandemic

Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study

Guillain-Barre syndrome in a patient with antibodies against SARS-COV-2

Guillain-Barre syndrome associated with SARS-CoV-2 infection: causality or coincidence?

COVID-19 may induce Guillain-Barre syndrome

Guillain-Barre syndrome during SARS-CoV-2 pandemic: A case report and review of recent literature

Guillain-Barre syndrome in a patient infected with SARS-CoV-2, a case report

Guillain-Barre syndrome related to COVID-19 infection

Early Guillain-Barre syndrome in coronavirus disease 2019 (COVID-19): a case report from an Italian COVID-hospital

Guillain-Barre syndrome following COVID-19: new infection, old complication?

Post-infectious Guillain-Barre syndrome related to SARS-CoV-2 infection: a case report

Guillain-Barre syndrome associated with SARS-CoV-2 infection

Guillain-Barre syndrome associated with leptomeningeal enhancement following SARS-CoV-2 infection

SARS-CoV-2, A new causative agent of Guillain-Barre syndrome?

SARS-CoV-2-associated Guillain-Barre syndrome with dysautonomia. Muscle Nerve

Guillain-Barre syndrome following COVID-19: a newly emerging post-infectious complication

Guillain-Barre syndrome associated with COVID-19 infection: a case from the UK

Guillain-Barre syndrome as a complication of SARS-CoV-2 infection

Guillain-Barre syndrome in the COVID-19 era: just an occasional cluster?

Guillain-Barre syndrome and COVID-19: association or coincidence

Guillain-Barre syndrome associated with severe acute respiratory syndrome coronavirus 2 detection and coronavirus disease 2019 in a child

Guillain-Barre syndrome related to SARS-CoV-2 infection

New clinical manifestation of COVID-19 related Guillain-Barre syndrome highly responsive to intravenous immunoglobulins: two Italian cases

Guillain-Barre syndrome in a patient with minimal symptoms of COVID-19 infection

Guillain-Barre syndrome with facial diplegia related to SARS-CoV-2 infection

Is Guillain-Barre syndrome triggered by SARS-CoV-2? Case report and literature review

Guillain-Barre syndrome after SARS-CoV-2 infection

Guillain-Barre syndrome after Covid-19 infection

Miller-Fisher syndrome after SARS-CoV-2 infection

Acute inflammatory demyelinating polyneuritis in association with an asymptomatic infection by SARS-CoV-2

Guillain-Barré syndrome as a neurological complication of COVID-19 infection: A case series and review of the literature

Guillain-Barré syndrome associated with the coronavirus disease 2019 (COVID-19)

Guillain-Barre Syndrome Associated with SARS-CoV-2

Clinical neurophysiology and cerebrospinal liquor analysis to detect Guillain-Barre syndrome and polyneuritis cranialis in COVID-19 patients: A case series

Guillain-Barre syndrome and SARS-CoV-2

Guillain-Barre syndrome in a patient with evidence of recent SARS-CoV-2 infection

The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings

Acute polyradiculoneuritis with locked-in syndrome in a patient with Covid-19

Novel coronavirus (COVID-19)-associated Guillain-Barre syndrome: case report

COVID-19 and Guillain-Barre syndrome case report

SARS-CoV-2 and Guillain-Barre syndrome: AIDP variant with a favourable outcome

Covid-19 and Guillain-Barre syndrome: more than a coincidence! Rev Neurol (Paris)

Guillain Barre syndrome associated with COVID-19 infection: A case report

COVID-19 and Guillain-Barre syndrome: a case report and review of literature

Guillain-Barre syndrome as a parainfectious manifestation of SARS-CoV-2 infection: A case series

Guillain-Barre syndrome associated with SARS-CoV-2 infection in a pediatric patient

Acute motor axonal neuropathy related to COVID-19 infection: a new diagnostic overview

COVID-19 polyradiculitis in 24 patients without SARS-CoV-2 in the cerebro-spinal fluid

COVID-19-associated bifacial weakness with paresthesia subtype of Guillain-Barre syndrome

Anti-pan-neurofascin IgM in COVID-19-related Guillain-Barre syndrome: evidence for a nodoparanodopathy

Guillain-Barre syndrome as a neurological complication of novel COVID-19 infection: a case report and review of the literature

Fatal Guillain-Barre syndrome after infection with SARS-CoV-2

Guillain-Barre syndrome associated with SARS-CoV-2 infection

Severe rapidly progressive Guillain-Barre syndrome in the setting of acute COVID-19 disease

Peripheral neuropathy in severe COVID-19 resolved with therapeutic plasma exchange

COVID-19-associated Miller Fisher syndrome: MRI findings

Miller-Fisher-like syndrome related to SARS-CoV-2 infection (COVID 19)

A case series of Guillain-Barré syndrome following Covid-19 infection in New York

Miller Fisher syndrome and polyneuritis cranialis in COVID-19

Miller Fisher syndrome diagnosis and treatment in a patient with SARS-CoV-2

GM1 ganglioside antibody and COVID-19 related Guillain Barre syndrome-case report, systemic review and implication for vaccine development

COVID-19 presenting with ophthalmoparesis from cranial nerve palsy

Autonomic dysfunction heralding acute motor axonal neuropathy in COVID-19

Association of Guillain-Barre syndrome with COVID-19: a case report and literature review

Guillain-Barre syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions

Incidence, clinical, risk factors and outcomes of Guillain-Barre in Covid-19

Guillain-Barre syndrome associated with Zika Virus infection in Colombia

The epidemiology of Guillain-Barre syndrome worldwide. A systematic literature review

Guillain-Barre syndrome

Guillain-Barre syndrome: pathogenesis, diagnosis, treatment and prognosis

Guillain-Barre syndrome

A multicentric prospective incidence study of Guillain-Barre syndrome in Italy. The ITANG study

Electrophysiological features of acute inflammatory demyelinating polyneuropathy associated with SARS-CoV-2 infection

Guillain-Barre syndrome: natural history and prognostic factors: a retrospective review of 106 cases

Guillain-Barre syndrome decreases in Singapore during the COVID-19 pandemic

Guillain-Barre syndrome after SARS-CoV-2 infection in an international prospective cohort study

Anosmia and olfactory tract neuropathy in a case of COVID-19

Inflammatory olfactory neuropathy in two patients with COVID-19

Optic neuropathy in a patient with COVID-19 infection

Coronavirus disease 2019-associated ocular neuropathy with panuveitis: a case report

Third cranial nerve palsy presenting with unilateral diplopia and strabismus in a 24-year-old woman with COVID-19

The 2019 novel cornoavirus pneumonia with onset of oculomotor nerve palsy: a case study

Coronavirus disease-19 pneumonia with facial nerve palsy and olfactory disturbance

COVID-19 myocarditis and postinfection Bell's palsy

Pearls & Oy-sters: Facial nerve palsy in COVID-19 infection

Facial nerve palsy: an atypical clinical manifestation of COVID-19 infection in a family cluster

Peripheral facial nerve palsy associated with COVID-19

Bell's palsy as a possible neurological complication of COVID-19: A case report

The great pretender-Bell's palsy secondary to SARS-CoV-2?

Lower motor neuron facial palsy in a postnatal mother with COVID-19

Bilateral facial nerve palsy associated with COVID-19 and Epstein-Barr virus coinfection

A 44-year-old Hispanic man with loss of taste and bilateral facial weakness diagnosed with Guillain-Barre syndrome and Bell's Palsy associated with SARS-CoV-2 infection treated with intravenous immunoglobulin

Facial diplegia, a possible atypical variant of Guillain-Barre syndrome as a rare neurological complication of SARS-CoV-2

A case of COVID-19 with multiple cranial neuropathies

COVID-19 and sudden sensorineural hearing loss, a case report

Could sudden sensorineural hearing loss be the sole manifestation of COVID-19? An investigation into SARS-COV-2 in the etiology of sudden sensorineural hearing loss

Acute profound sensorineural hearing loss after COVID-19 pneumonia

Tapia syndrome at the time of the COVID-19 pandemic: Lower cranial neuropathy following prolonged intubation

Selective cranial multineuritis in severe COVID-19 pneumonia: two cases and literature review

Hypoglossal Nerve Palsy as a COVID-19 Sequel

Isolated Cranial Nerve 6 Palsy in 6 Patients With COVID-19 Infection

Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study

Objective evaluation of anosmia and ageusia in COVID-19 patients: Single-center experience on 72 cases

Magnetic resonance imaging alteration of the brain in a patient with coronavirus disease 2019 (COVID-19) and anosmia

Retinal findings in patients with COVID-19

Retinal findings in hospitalised patients with severe COVID-19

Retinal findings in patients affected by COVID 19 intubated in an intensive care unit

Retinal findings in patients with COVID-19: results from the SERPICO-19 study

Facial palsy during the COVID-19 pandemic

Increased childhood peripheral facial Palsy in the emergency department during COVID-19 pandemic

Facial paralysis as the only symptom of COVID-19: A prospective study

Persistent selfreported changes in hearing and tinnitus in post-hospitalisation COVID-19 cases

Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study

Exacerbation of chronic inflammatory demyelinating polyneuropathy in concomitance with COVID-19

COVID-19-induced exacerbation of chronic inflammatory demyelinating polyneuropathy

COVID-19 vasculitis and novel vasculitis mimics

Mononeuritis multiplex: an unexpectedly frequent feature of severe COVID-19

Mononeuritis multiplex associated with Sars-Cov2-Covid-19 Infection: case report

Peripheral polyneuropathy associated with COVID-19 in two patients: A musculoskeletal ultrasound case report

Brachial plexopathy as a complication of COVID-19

Rhabdomyolysis in COVID-19 patients: a retrospective observational study

SARS-CoV-2 infection presenting as rhabdomyolysis: case report and review

Rhabdomyolysis and acute kidney injury in severe COVID-19 infection

Myositis as a manifestation of SARS-CoV-2

A rare presentation of coronavirus disease 2019 (COVID-19) induced viral myositis with subsequent rhabdomyolysis

COVID-19-associated myositis with severe proximal and bulbar weakness

Dermatomyositis during COVID-19 Pandemic (a case series): is there a cause effect relationship?

Paraspinal myositis in patients with COVID-19 infection

Compartment syndrome secondary to viral myositis as initial presentation in COVID-19 patient

Severe acute myopathy following SARS-CoV-2 infection: a case report and review of recent literature

Clinically amyopathic dermatomyositis during the COVID-19 pandemic

COVID-19 or clinical amyopathic dermatomyositis associated rapidly progressive interstitial lung disease? A case report

Pulmonary and systemic involvement in COVID-19 patients assessed with ultrasound-guided minimally invasive autopsy

New onset of ocular myasthenia gravis in a patient with COVID-19: a novel case report and literature review

Myasthenia gravis associated with SARS-CoV-2 infection

Postinfectious onset of myasthenia gravis in a COVID-19 patient

MuSK antibody-associated myasthenia gravis with SARS-CoV-2 infection: a case report

Myasthenia gravis associated with anti-MuSK antibodies developed after SARS-CoV-2 infection

COVID-19 in muscle-specific kinase myasthenia gravis: A case report

COVID-19 in patients with myasthenia gravis

Myasthenia gravis and COVID-19: clinical characteristics and outcomes

Management of patients with generalised myasthenia gravis and COVID-19: four case reports

Electronic health record derived-impact of COVID-19 on myasthenia gravis

COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)

COVID-19 in patients with myasthenia gravis: epidemiology and disease course

Impact of coronavirus disease 2019 in a French cohort of myasthenia gravis

Myasthenia gravis and COVID-19: A case series and comparison with literature

Neuromuscular involvement in COVID-19 critically ill patients

Acute myopathic quadriplegia in patients with COVID-19 in the intensive care unit

The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial

High-dose intravenous immunoglobulins as a therapeutic option in critical illness polyneuropathy accompanying SARS-CoV-2 infection: A case-based review of the literature (Review)

Prone positioning in severe acute respiratory distress syndrome

Injury-prone: peripheral nerve injuries associated with prone positioning for COVID-19-related acute respiratory distress syndrome

Nerve compression injuries after prolonged prone position ventilation in patients with SARS-CoV-2: a case series

Brachial plexus neuropathies during the COVID-19 pandemic: a retrospective case series of 15 patients in critical care

Ulnar neuropathy after intermittent prone positioning for COVID-19 infection: A preliminary report of 3 cases

Upper trunk brachial plexopathy as a consequence of prone positioning due to SARS-CoV-2 acute respiratory distress syndrome

Lateral femoral cutaneous neuropathy caused by prone positioning to treat COVID-19-associated acute respiratory distress syndrome

Lessons from an ICU recovery clinic: two cases of meralgia paresthetica after prone positioning to treat COVID-19-associated ARDS and modification of unit practices

Post-acute COVID-19 syndrome

Post-COVID-19 syndrome: epidemiology, diagnostic criteria and pathogenic mechanisms involved

Four-month clinical status of a cohort of patients after hospitalization for COVID-19

Long COVID in a prospective cohort of home-isolated patients

Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19

Frequent neurocognitive deficits after recovery from mild COVID-19

Pain during and after COVID-19 in Germany and worldwide: a narrative review of current knowledge

Does COVID-19-related cachexia mimic cancer-related cachexia? Examining mechanisms, clinical biomarkers, and potential targets for clinical management

Persistent symptoms in patients after acute COVID-19

Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection: a case series of 20 patients

Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies

Autonomic dysfunction following COVID-19 infection: an early experience

Sudomotor dysfunction in patients recovered from COVID-19

Small fiber neuropathy associated with SARS-CoV-2 infection. Muscle Nerve

Myalgic encephalomyelitis/chronic fatigue syndrome: essentials of diagnosis and management

Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Safety and efficacy of NVX-CoV2373 Covid-19 vaccine

Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials

COVID-19 vaccination and non-COVID-19 mortality risk-seven integrated health care organizations, United States

Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory committee on immunization practices -United States

Myocarditis after Covid-19 vaccination in a large health care organization

Vaccines and Guillain-Barre syndrome

Guillain-Barre syndrome in the placebo and active arms of a COVID-19 vaccine clinical trial: temporal associations do not imply causality

Guillain-Barre syndrome following first injection of ChAdOx1 nCoV-19 vaccine: first report

Guillain-Barre syndrome following the first dose of SARS-CoV-2 vaccine: a temporal occurrence, not a causal association

Case of Guillain-Barre syndrome following COVID-19 vaccine

Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1

A variant of Guillain-Barre syndrome after SARS-CoV-2 vaccination: AMSAN

Neurological complications of COVID-19: Guillain-Barre syndrome following Pfizer COVID-19 vaccine

Post-COVID-19 vaccine Guillain-Barre syndrome; first reported case from Qatar

A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine

Bilateral facial weakness with paraesthesia variant of Guillain-Barre syndrome following Vaxzevria COVID-19 vaccine

Guillain-Barre syndrome after COVID-19 vaccination

Guillain-Barre syndrome following ChAdOx1 nCoV-19 COVID-19 vaccination: A case series

Guillain-Barre syndrome following BNT162b2 COVID-19 vaccine

Electromyoneurography and laboratory findings in a case of Guillain-Barre syndrome after second dose of Pfizer COVID-19 vaccine

AstraZeneca COVID-19 vaccine and Guillain-Barre syndrome in Tasmania: a causal link?

Sensory Guillain-Barre syndrome following the ChAdOx1 nCov-19 vaccine: Report of two cases and review of literature

Acute-onset polyradiculoneuropathy after SARS-CoV2 vaccine in the West and North Midlands, United Kingdom

Guillain-Barre Syndrome variant occurring after SARS-CoV-2 vaccination

Guillain-Barre syndrome following ChAdOx1-S/nCoV-19 vaccine

Association of receipt of the Ad26.COV2.S COVID-19 vaccine with presumptive Guillain-Barre syndrome

Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection

Guillain-Barre syndrome associated with COVID-19 vaccination

Guillain-Barre syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine

Surveillance for adverse events after COVID-19 mRNA vaccination

Mechanisms of Immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection

COVID-19 vaccine and Guillain-Barre syndrome: let's not leap to associations

Population incidence of Guillain-Barre syndrome: a systematic review and meta-analysis

Bell's palsy and SARS-CoV-2 vaccines

Bell's palsy following COVID-19 vaccination

Bell's Palsy after second dose of Pfizer COVID-19 vaccination in a patient with history of recurrent Bell's palsy

Sequential contralateral facial nerve palsies following COVID-19 vaccination first and second doses

Peripheral facial nerve palsy following BNT162b2 (COVID-19) vaccination

Ophthalmic complications of COVID-19 vaccination

Acute abducens nerve palsy following COVID-19 vaccination

Acute abducens nerve palsy after COVID-19 vaccination in a young adult

Multiple cranial nerve palsies following COVID-19 vaccination-case report

Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination

Motor palsies of cranial nerves (excluding VII) after vaccination: reports to the US vaccine adverse event reporting system

Guillain-Barré syndrome, or acute on chronic inflammatory demyelinating polyneuropathy, following Moderna Covid-19 vaccine

Acute-onset chronic inflammatory demyelinating polyneuropathy after COVID-19 infection and subsequent ChAdOx1 nCoV-19 vaccination

Risk factors for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): antecedent events, lifestyle and dietary habits. Data from the Italian CIDP Database

Recurrences, vaccinations and long-term symptoms in GBS and CIDP

Risk of relapse of Guillain-Barre syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunisation

Immunization and risk of relapse of Guillain-Barre syndrome or chronic inflammatory demyelinating polyradiculoneuropathy

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and vaccinations: examining the current literature on vaccinations and the onset or worsening of CIDP symptoms

US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination

Parsonage-Turner syndrome after SARS-CoV-2 BNT162b2 vaccine: a case report

Neuralgic amyotrophy following COVID-19 mRNA vaccination

Parsonage Turner syndrome after COVID-19 vaccination

Parsonage-Turner syndrome following coronavirus disease 2019 immunization with ChAdOx1-S vaccine: a case report and review of the literature

Painless idiopathic neuralgic amyotrophy after COVID-19 vaccination: A case report

Leg paralysis after AstraZeneca COVID-19 vaccination diagnosed as neuralgic amyotrophy of the lumbosacral plexus: a case report

Amyotrophic neuralgia secondary to Vaxzevri (AstraZeneca) COVID-19 vaccine

Parsonage-Turner syndrome following COVID-19 Vaccination: MR neurography

Reactogenicity following receipt of mRNA-based COVID-19 vaccines

COVID-19 vaccine induced rhabdomyolysis: case report with literature review

Rhabdomyolysis secondary to COVID-19 vaccination

COVID-19 vaccine-related myositis

Myositis ossificans following COVID-19 vaccination

COVID-19 mRNA vaccine induced rhabdomyolysis and fasciitis

Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID symptom study app: a prospective, community-based, nested, case-control study

The environment and disease: association or causation?

COVID-19 and neurologic manifestations: a still missing link and a call for neurologists

Rate of recurrent Guillain-Barre syndrome after mRNA COVID-19 vaccine BNT162b2

AANEM Quality and Patient Safety Committee. Doctor-Should I get the COVID-19 vaccine? Infection and immunization in individuals with neuromuscular disorders

Acute and chronic inflammatory neuropathies and COVID-19 vaccines: practical recommendations from the task force of the Italian Peripheral Nervous System Association (ASNP)

COVID-19 and the peripheral nervous system. A 2-year review from the pandemic to the vaccine era

The authors declare no potential conflict of interest.

https://orcid.org/0000-0001-7059-3604Giuseppe Lauria https://orcid.org/0000-0001-9773-020X